Seeking Clarity on Transparency

Draft transparency proposals released by an FDA task force would, if implemented, give the public, investors, competitors and researchers unprecedented insight into both the agency's decisions and the reasons it makes those decisions.

The most controversial proposal is to publicly release complete response and refuse-to-file letters for drugs and biologics, and not approvable letters for devices, at the time they are sent to sponsors...